Literature DB >> 23814159

Personalized cancer medicine: are we there yet?

Mark Lawler1, Peter Selby.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23814159      PMCID： PMC4063386          DOI： 10.1634/theoncologist.2013-0189

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

Review 1.  Melanoma in 2011: a new paradigm tumor for drug development.

Authors:  Alexander M M Eggermont; Caroline Robert
Journal:  Nat Rev Clin Oncol       Date:  2012-01-10       Impact factor: 66.675

2.  Personalized medicine: does the molecular suit fit?

Authors:  Edison T Liu; Patrick G Johnston
Journal:  Oncologist       Date:  2013-06

3.  Cancer clinical trials--do we need a new algorithm in the age of stratified medicine?

Authors:  James H Doroshow; Stefan Sleijfer; Roger Stupp; Kenneth Anderson
Journal:  Oncologist       Date:  2013-06

4.  Perspectives on the development of imatinib and the future of cancer research.

Authors:  Brian J Druker
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

5.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  D D Von Hoff
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

Review 6.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

7.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.